— Know what they know.
/
Not Investment Advice

ZBIO NASDAQ

Zenas BioPharma, Inc.
1W: +5.0% 1M: -14.6% 3M: +7.0% YTD: -18.0% 1Y: +27.9%
$28.30
+0.35 (+1.27%)
 
Weekly Expected Move ±7.7%
$24 $26 $28 $30 $33
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 37 · $1.8B mcap · 15M float · 5.33% daily turnover · Short 56% of daily vol
Overview News Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings
Dividends Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest Supply Chain

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
45.2 / 100
NoneWeakNarrowWide
Primary source: Switching Costs  ·  ROIC: 5842.1%
Cost Advantage
44
Intangibles
41
Switching Cost
60
Network Effect
47
Scale
27
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. ZBIO shows a Weak competitive edge (45.2/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Switching Costs. ROIC of 5842.1% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$32
Low
$44
Avg Target
$55
High
Based on 2 analysts since Aug 12, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 4Hold: 1Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$43.50
Analysts2
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-09-30 Guggenheim Yatin Suneja Initiated $55 — +105.5% $26.76
2026-08-14 Morgan Stanley — $22 $32 +10 +7.2% $29.84
2026-05-14 Morgan Stanley — $19 $22 +3 +13.2% $19.43
2026-01-06 Jefferies Roger Song $52 $48 -4 +189.0% $16.61
2026-01-05 Morgan Stanley — $34 $19 -15 +14.4% $16.61
2025-10-28 H.C. Wainwright — Initiated $44 — +48.3% $29.67
2025-10-27 Morgan Stanley Sean Laaman Initiated $34 — +7.4% $31.65
2025-10-27 Jefferies Roger Song $35 $52 +17 +63.5% $31.80
2024-10-08 Jefferies Roger Song Initiated $35 — +87.2% $18.70

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

D+
Oct 02, 2026
DCF
1
ROE
1
ROA
1
D/E
1
P/E
1
P/B
1
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. ZBIO receives an overall rating of D+. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (1/5), P/E (1/5), P/B (1/5).
Rating Change History
DateFromTo
2026-05-18 C- D+
2026-05-13 D+ C-
2026-03-23 C- D+
2026-03-16 C+ C-
2026-01-12 B- C+
2026-01-12 C+ B-
2026-01-07 B- C+
2026-01-05 C+ B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 9 Grade D
Profitability
20
Balance Sheet
11
Earnings Quality
18
Growth
12
Value
32
Momentum
20
Safety
0
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. ZBIO scores highest in Value (32/100) and lowest in Safety (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
-0.94
Distress Zone
Piotroski F-Score
2/9
✗ ✗ ✗ ✓ ✗ ✓ ✗ ✗ ✗
Beneish M-Score
—
—
Ohlson O-Score
-3.82
Bankruptcy prob: 2.1%
Low Risk
Credit Rating
B
Score: 26.7/100
Trend: Deteriorating
Earnings Quality
—
OCF/NI: 0.47x
Accruals: -52.0%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. ZBIO scores -0.94, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. ZBIO scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. ZBIO's implied 2.1% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. ZBIO receives an estimated rating of B (score: 26.7/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-2.94x
PEG
0.03x
P/S
1786.36x
P/B
7.23x
P/FCF
-7.09x
P/OCF
—
EV/EBITDA
-2.95x
EV/Revenue
1348.26x
EV/EBIT
-2.95x
EV/FCF
-5.97x
Earnings Yield
-30.24%
FCF Yield
-14.11%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. ZBIO currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.000
NI / EBT
×
Interest Burden
1.059
EBT / EBIT
×
EBIT Margin
-457.311
EBIT / Rev
×
Asset Turnover
0.002
Rev / Assets
×
Equity Multiplier
2.044
Assets / Equity
=
ROE
-199.0%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. ZBIO's ROE of -199.0% is driven by Asset Turnover (0.002), indicating efficient use of assets to generate revenue. A tax burden ratio of 1.00 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 514 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$28.30
Median 1Y
$19.77
5th Pctile
$3.12
95th Pctile
$125.93
Ann. Volatility
108.2%
Analyst Target
$43.50
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Leon O. Moulder,
Jr. Founder, Chief Executive Officer and Chairman
 $520,000 $— $4,661,000
Lisa von Moltke,
M.D Head of Research and Development and Chief Medical Officer
 $411,667 $— $3,499,447
Joseph L. Farmer
President and Chief Operating Officer
 $520,000 $— $2,526,525

CEO Pay Ratio

15:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $4,661,000
Avg Employee Cost (SGA/emp): $319,293
Employees: 167

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
167
+28.5% YoY
Revenue / Employee
$59,880
Rev: $10,000,000
Profit / Employee
$-2,261,898
NI: $-377,737,000
SGA / Employee
$319,293
Avg labor cost proxy
R&D / Employee
$1,006,365
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -10.7% -29.2% -43.9% -73.9% -68.3% -1.4% -1.4% -2.0% -1.99%
ROA -9.6% -24.7% -37.4% -60.4% -52.4% -1.0% -78.6% -97.4% -97.39%
ROIC 1.2% 2.0% 3.9% 4.6% 1.7% 14.4% 11.3% 58.4% 58.42%
ROCE -11.4% -30.9% -45.8% -77.4% -72.7% -1.2% -59.9% -71.9% -71.92%
Gross Margin — 1.0% 1.0% — — — — 1.0% 1.00%
Operating Margin — -11.1% -3.7% — — — — -107.7% -107.66%
Net Margin — -10.5% -3.4% — — — — -111.5% -111.46%
EBITDA Margin — -11.1% -3.4% — — — — -101.0% -101.04%
FCF Margin — -13.9% -7.1% -9.9% -10.6% -17.2% — -226.0% -225.97%
OCF Margin — -13.9% -7.1% -9.9% -10.6% -17.2% — -226.0% -225.97%
ROIC Economic snapshot only -59.01%
Cash ROA snapshot only -32.20%
NOPAT Margin snapshot only -375.70%
Pretax Margin snapshot only -484.16%
R&D / Revenue snapshot only 213.47%
SGA / Revenue snapshot only 61.42%
SBC / Revenue snapshot only 32.73%
Valuation
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -18.31 -3.75 -2.65 -2.29 -4.93 -4.47 -2.56 -3.31 -2.941
P/S Ratio — 68.45 22.02 27.05 62.40 168.82 — 1601.79 1786.359
P/B Ratio 1.97 1.10 1.16 1.69 4.76 6.97 3.24 6.48 7.227
P/FCF -22.76 -4.91 -3.09 -2.73 -5.90 -9.80 -5.17 -7.09 -7.088
P/OCF — — — — — — — — —
EV/EBITDA -7.83 0.08 -0.15 -0.72 -3.30 -3.84 -1.75 -2.95 -2.948
EV/Revenue — -1.50 1.27 8.89 43.06 142.50 — 1348.26 1348.263
EV/EBIT -7.82 0.08 -0.15 -0.72 -3.29 -3.84 -1.75 -2.95 -2.948
EV/FCF -10.32 0.11 -0.18 -0.90 -4.07 -8.27 -3.43 -5.97 -5.966
Earnings Yield -5.5% -26.6% -37.8% -43.6% -20.3% -22.4% -39.1% -30.2% -30.24%
FCF Yield -4.4% -20.4% -32.3% -36.6% -16.9% -10.2% -19.4% -14.1% -14.11%
PEG Ratio snapshot only 0.033
Price/Tangible Book snapshot only 6.482
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 8.95 6.21 6.47 5.23 5.66 5.61 11.94 9.93 9.933
Quick Ratio 8.95 6.21 6.47 5.23 5.66 5.61 11.94 9.93 9.933
Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.33 1.05 1.58 1.577
Net Debt/Equity -1.08 -1.12 -1.09 -1.14 -1.48 -1.09 -1.09 -1.03 -1.026
Debt/Assets 0.00 0.00 0.00 0.00 0.00 0.21 0.47 0.56 0.555
Debt/EBITDA -0.01 -0.01 -0.01 -0.01 -0.00 -0.22 -0.85 -0.85 -0.852
Net Debt/EBITDA 9.44 3.62 2.39 1.47 1.48 0.71 0.89 0.55 0.554
Interest Coverage — — — — — — -62.05 -27.01 -27.007
Equity Multiplier 1.12 1.18 1.17 1.22 1.64 1.58 2.23 2.84 2.840
Cash Ratio snapshot only 9.771
Debt Service Coverage snapshot only -27.005
Cash to Debt snapshot only 1.651
FCF to Debt snapshot only -0.580
Defensive Interval snapshot only 498.4 days
Efficiency & Turnover
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.00 0.01 0.04 0.05 0.04 0.03 0.00 0.00 0.002
Inventory Turnover — — — — — — — — —
Receivables Turnover — — — — — — 0.00 2.50 2.500
Payables Turnover 2.22 1.96 1.67 9.65 4.46 3.96 3.32 0.65 0.645
DSO — 0 0 0 0 0 — 146 146.0 days
DIO 0 0 0 0 0 0 0 0 0.0 days
DPO 164 187 218 38 82 92 110 566 565.8 days
Cash Conversion Cycle — -187 -218 -38 -82 -92 — -420 -419.8 days
Fixed Asset Turnover snapshot only 1.185
Cash Velocity snapshot only 0.002
Capital Intensity snapshot only 701.690
Growth (YoY)
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue — — — — — 1.0% -1.0% -93.3% -93.33%
Net Income — — — — -3.9% -3.1% -2.4% -1.7% -1.74%
EPS — — — — -3.9% -2.7% -1.6% -81.5% -81.53%
FCF — — — — -4.1% -1.5% -97.2% -52.2% -52.17%
EBITDA — — — — -3.8% -2.8% -2.2% -1.5% -1.47%
Op. Income — — — — -3.9% -3.0% -2.2% -1.5% -1.51%
OCF Growth snapshot only -52.27%
Asset Growth snapshot only 1.39%
Equity Growth snapshot only 3.12%
Debt Growth snapshot only 385.51%
Shares Change snapshot only 50.75%
Growth Quality
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability — — — — — — — — —
Earnings Stability — — — — — — — — —
Margin Stability — — — — — — — — —
Rev. Growth Consistency 0.00 0.00 0.00 0.00 0.50 0.50 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0
Earnings Persistence — — — — — — — — —
Earnings Smoothness — — — — — — — — —
ROE Trend — — — — — — — — —
Gross Margin Trend — — — — — — — — —
FCF Margin Trend — — — — — — — — —
Sustainable Growth Rate — — — — — — — — —
Internal Growth Rate — — — — — — — — —
Cash Flow Quality
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.80 0.76 0.85 0.84 0.83 0.46 0.50 0.47 0.467
FCF/OCF 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF/Net Income snapshot only 0.467
CapEx/Revenue — 1.5% 0.6% 0.6% 0.6% 0.2% — 0.2% 0.20%
CapEx/Depreciation snapshot only 0.065
Accruals Ratio -0.02 -0.06 -0.05 -0.10 -0.09 -0.55 -0.40 -0.52 -0.520
Sloan Accruals snapshot only 0.729
Cash Flow Adequacy snapshot only -112986.000
Dividends & Buybacks
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — —
FCF Payout Ratio — — — — — — — — —
Total Payout Ratio — — — — — — — — —
Div. Increase Streak — — — — — — — — —
Chowder Number — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield -33.2% -70.3% -72.9% -59.8% -1.0% -9.1% -29.4% -20.8% -20.76%
Total Shareholder Return -33.2% -70.3% -72.9% -59.8% -1.0% -9.1% -29.4% -20.8% -20.76%
DuPont Factors
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Interest Burden (EBT/EBIT) 0.94 0.94 0.96 0.95 0.97 1.02 1.03 1.06 1.059
EBIT Margin — -19.32 -8.69 -12.37 -13.07 -37.09 — -457.31 -457.311
Asset Turnover 0.00 0.01 0.04 0.05 0.04 0.03 0.00 0.00 0.002
Equity Multiplier 1.12 1.18 1.17 1.22 1.31 1.36 1.74 2.04 2.044
Per Share
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.92 $-2.18 $-2.99 $-4.23 $-4.50 $-8.12 $-7.64 $-7.67 $-7.67
Book Value/Share $8.60 $7.48 $6.80 $5.72 $4.66 $5.21 $6.04 $3.92 $3.92
Tangible Book/Share $8.60 $7.48 $6.80 $5.72 $4.66 $5.21 $6.04 $3.92 $3.92
Revenue/Share $0.00 $0.12 $0.36 $0.36 $0.36 $0.22 $0.00 $0.02 $0.02
FCF/Share $-0.74 $-1.67 $-2.55 $-3.55 $-3.76 $-3.71 $-3.78 $-3.58 $-3.58
OCF/Share $-0.74 $-1.67 $-2.55 $-3.54 $-3.76 $-3.71 $-3.78 $-3.58 $-3.58
Cash/Share $9.26 $8.39 $7.47 $6.53 $6.90 $7.38 $12.89 $10.19 $10.19
EBITDA/Share $-0.98 $-2.31 $-3.12 $-4.43 $-4.65 $-7.98 $-7.40 $-7.25 $-7.25
Debt/Share $0.01 $0.02 $0.03 $0.02 $0.02 $1.72 $6.32 $6.17 $6.17
Net Debt/Share $-9.25 $-8.37 $-7.44 $-6.50 $-6.88 $-5.66 $-6.57 $-4.02 $-4.02
Academic Models
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — -0.940
Altman Z-Prime snapshot only 0.368
Piotroski F-Score 2 2 2 2 2 2 2 2 2
Beneish M-Score — — — — — — — — —
Ohlson O-Score snapshot only -3.821
ROIC (Greenblatt) snapshot only -77.67%
Net-Net WC snapshot only $3.16
Credit
Metric Trend Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only B
Credit Score 76.07 59.55 59.88 49.41 49.37 58.14 28.09 26.72 26.722
Credit Grade snapshot only 15
Credit Trend snapshot only -22.692
Implied Spread (bps) snapshot only 750.000
Industry Credit Rank snapshot only 16
Sector Credit Rank snapshot only 17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms